Lydia Stone Sells 6,805 Shares of Evolent Health Inc (EVH) Stock
Evolent Health Inc (NYSE:EVH) insider Lydia Stone sold 6,805 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $25.00, for a total transaction of $170,125.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
EVH opened at $24.50 on Friday. Evolent Health Inc has a one year low of $10.30 and a one year high of $25.82. The company has a current ratio of 2.59, a quick ratio of 2.59 and a debt-to-equity ratio of 0.12. The company has a market cap of $1.92 billion, a PE ratio of -35.00 and a beta of 1.22.
Evolent Health (NYSE:EVH) last released its quarterly earnings results on Tuesday, August 7th. The technology company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. Evolent Health had a negative net margin of 9.84% and a negative return on equity of 1.82%. The business had revenue of $144.51 million for the quarter, compared to analysts’ expectations of $141.90 million. equities analysts anticipate that Evolent Health Inc will post -0.34 EPS for the current fiscal year.
Several analysts have recently weighed in on EVH shares. SunTrust Banks raised their price objective on shares of Evolent Health and gave the stock a “buy” rating in a report on Thursday, June 7th. Zacks Investment Research raised shares of Evolent Health from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a report on Monday, May 14th. Piper Jaffray Companies started coverage on shares of Evolent Health in a report on Monday, June 4th. They set an “overweight” rating and a $30.00 price objective for the company. KeyCorp raised their price objective on shares of Evolent Health from $26.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, August 20th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Evolent Health in a report on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company. Evolent Health currently has a consensus rating of “Buy” and a consensus target price of $26.92.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Article: Trading Strategy Methods and Types
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.